Adoptive cell transfer therapy for hepatocellular carcinoma
Adoptive cell transfer therapy for hepatocellular carcinoma
复制标题
肝细胞癌的过继细胞移植疗法
DOI：
10.1007/s11684-019-0684-x
复制
发表时间：
2019-01
影响因子：
8.1
通讯作者：
Chen Zhinan
中科院分区：
文献类型：
--
作者：
Zhang Renyu;Zhang Zhao;Liu Zekun;Wei Ding;Wu Xiaodong;Bian Huijie;Chen Zhinan
肝细胞癌是世界范围内最常见的癌症之一。这种恶性肿瘤与预后不良和高死亡率有关。迫切需要新的方法来延长晚期肝细胞癌患者的总体生存时间。过继细胞转移疗法(ACT)的抗肿瘤活性，如基于肿瘤浸润性淋巴细胞和细胞因子诱导的杀伤细胞的策略，比传统策略更有效。目前，嵌合抗原受体T细胞(CAR-T)免疫治疗在治疗包括复发或难治性淋巴母细胞白血病和难治性大B细胞淋巴瘤在内的血液系统恶性肿瘤方面取得了许多突破。然而，这种方法在实体肿瘤的治疗中只提供了不大的好处。目前，CAR-T免疫治疗肝癌的临床效果有限。一些已发表的研究表明，CAR-T可以抑制肿瘤生长，并引起严重的副作用。本文综述了ACT的应用现状，CAR-T技术在肝癌治疗中面临的挑战，以及未来免疫治疗研究方向的可能策略。
Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide. This malignancy is associated with poor prognosis and high mortality. Novel approaches for prolonging the overall survival of patients with advanced HCC are urgently needed. The antitumor activities of adoptive cell transfer therapy (ACT), such as strategies based on tumor-infiltrating lymphocytes and cytokine-induced killer cells, are more effective than those of traditional strategies. Currently, chimeric antigen receptor T-cell (CAR-T) immunotherapy has achieved numerous breakthroughs in the treatment of hematological malignancies, including relapsed or refractory lymphoblastic leukemia and refractory large B-cell lymphoma. Nevertheless, this approach only provides a modest benefit in the treatment of solid tumors. The clinical results of CAR-T immunotherapy for HCC that could be obtained at present are limited. Some published studies have demonstrated that CAR-Tcould inhibit tumor growth and cause severe side effects. In this review, we summarized the current application of ACT, the challenges encountered by CAR-T technology in HCC treatment, and some possible strategies for the future direction of immunotherapeutic research.
登录
查看更多内容
DOI：
10.1038/nrclinonc.2017.148
发表时间：
2018-01
期刊：
Nature reviews. Clinical oncology
影响因子：
--
作者：
Neelapu SS;Tummala S;Kebriaei P;Wierda W;Gutierrez C;Locke FL;Komanduri KV;Lin Y;Jain N;Daver N;Westin J;Gulbis AM;Loghin ME;de Groot JF;Adkins S;Davis SE;Rezvani K;Hwu P;Shpall EJ
通讯作者：
Shpall EJ
影响因子：
82.9
作者：
Mount CW;Majzner RG;Sundaresh S;Arnold EP;Kadapakkam M;Haile S;Labanieh L;Hulleman E;Woo PJ;Rietberg SP;Vogel H;Monje M;Mackall CL
通讯作者：
Mackall CL
影响因子：
29.4
作者：
Lee, Joon Hyeok;Lee, Jeong-Hoon;Yoon, Jung-Hwan
通讯作者：
Yoon, Jung-Hwan
影响因子：
158.5
作者：
Llovet, Josep M.;Ricci, Sergio;Bruix, Jordi
通讯作者：
Bruix, Jordi
[131I]美妥昔单抗治疗经皮射频消融术后肝细胞癌的随机试验。
影响因子：
10.3
作者：
Bian, Huijie;Zheng, Jia-Sheng;Chen, Zhi-Nan
通讯作者：
Chen, Zhi-Nan